BioCentury
ARTICLE | Clinical News

JVS-100: Phase II started

August 27, 2012 7:00 AM UTC

Juventas began the double-blind, placebo-controlled U.S. Phase II STOP-HF trial to evaluate single doses of 15 and 30 mg JVS-100 delivered via endomyocardial injection with the Helical Infusion System from BioCardia Inc. (San Carlos, Calif.) in about 90 patients with ischemic heart failure. Juventas is also evaluating JVS-100 in the Phase IIa STOP-CLI trial to treat critical limb ischemia (CLI). ...